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Retroviruses, such as HIV-1, are enveloped RNA viruses
that use the enzyme reverse transcriptase (RT) to make
a DNA copy of their RNA genome during replication in
the host cell. The retrovirus life cycle is generally divided
into two distinct phases: the early and late phase. The early
phase encompasses virion entry into the host cell, reverse
transcription of the viral RNA, nuclear import of the pre-
integration complex (PIC), and integration of viral DNA into
the host chromosome. The late phase involves transcription
of viral DNA to multiple copies of viral RNA, translation
of viral proteins, traﬃcking of viral proteins and genome
to assembly sites, budding of viral particles, and, finally,
maturation. A number of host factors have been implicated
in specific steps of virus replication, and identification of
such factors is a rapidly growing field. Recently, many host
proteins were identified in genome-wide siRNA screens as
being required for HIV-1 replication [1–3].
Over 25 antiretroviral drugs are currently in clinical use
for treating HIV-1, and except for the fusion inhibitor that
targets the viral envelope glycoprotein gp41 or the coreceptor
CCR5, these drugs target the activity of the viral enzymes
RT, integrase (IN), and protease (PR) [4–8]. The advent of
highly active antiretroviral therapy (HAART) has made a
significant impact on the natural history of HIV/AIDS by
dramatically prolonging the life of HIV-infected individuals
[9]. However, besides long-term drug toxicity and drug-
drug interactions leading to treatment failures, significant
limitations of antiviral therapy include the emergence of
drug-resistant viral variants [10]. Further, the success of top-
ical and oral preexposure prophylaxis (PrEP) in preventing
the sexual transmission of HIV in a clinical trial setting
presents potential concern because antiretrovirals or drugs
with similar resistance profiles are used both for therapy
and prevention [11]. This, in a PrEP setting, could either
result in the transmission of drug-resistant viral strains or
the generation of such viral strains in individuals taking
PrEP unaware of their HIV infection status, thereby limiting
future therapeutic options. Such concerns warrant eﬀorts to
identify novel inhibitors of HIV. Understanding the role of
host proteins in viral replication could potentially lead to
the development of new therapeutic strategies to combat this
deadly pathogen.
This special issue brings together 17 reviews by experts
on various aspects of the HIV-1 life cycle, highlighting the
significant roles played by host factors in virus replication,
and the antiviral agents that act on the viral and cellular
targets. These reviews do not necessarily represent an
exhaustive inventory of the current state of research or
opinion in the field. Instead, the reviews cover the widely
studied host-factors in each step of the HIV-1 replication
cycle and antiviral therapy targeting viable cellular and viral
targets. We, the guest editors, would like to sincerely thank
all the authors for their contribution to this special issue and
the reviewers for their time and expertise.
In his review “TRIM5 and the regulation of HIV-1
infectivity,” Jeremy Luban oﬀers an in-depth analysis of
how TRIM5 impedes retroviral infection, including the
recent exciting data concerning TRIM5’s innate immune
signaling capacity that permits the host factor to recognize
HIV-1’s capsid (CA) lattice and subsequently signal to
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downstream antiviral eﬀectors. This review also presents
a comprehensive picture of a major challenge facing the
field today—understanding the structural basis of TRIM5’s
recognition of HIV-1 CA.
Esposito and colleagues review the structure and func-
tion of the HIV-1 RT and the mode of action of nucleo-
side/nucleotide reverse transcriptase inhibitors (NRTIs) and
nonnucleoside reverse transcriptase inhibitors (NNRTIs).
The authors discuss novel RT inhibitors that are currently
in development, including NRTIs that act as chain termi-
nators and those that act by blocking RT translocation or
delaying DNA chain termination. New NNRTIs designed to
inhibit HIV-1 mutants resistant to first-generation NNRTIs
such as nevirapine and efavirenz, and those that block
RT by competing with nucleotide substrate, a mechanism
distinct from classical NNRTIs, are also covered in this
review. Further, the authors highlight RNaseH inhibitors
and pyrophosphate analogues andmolecules that disrupt the
essential RT subunit interaction.
Sheehy and Erthal in their exceptionally well-written
review “APOBEC3 versus retroviruses, immunity versus inva-
sion: Clash of the Titans” deftly touch on the major advances
in understanding the role of this fascinating antiretroviral
protein, and highlight some compelling future topics for
research. The authors also cover the latest in vivo observa-
tions on APOBEC3 functions in HIV-infected patients.
Macrophages are a key source of HIV persistence in
vivo. The review by Gavegnano and colleagues describes how
nucleotide pools diﬀer in macrophages compared to actively
dividing T lymphocytes. Specifically, dNTP levels are limited
relative to high levels of rNTPs and this disparity, shaped by
the myeloid-cell-specific restriction factor SAMHD1, leads
to preferential incorporation of rNTPs compared to dNTPs
during reverse transcription. The authors discuss how the
incorporation of rNTPs in the nascent viral DNA strand,
which dispels the dogma that RT can only incorporate
dNTPs, can be exploited in the design ribonucleoside chain
terminator inhibitors that block HIV replication specifically
in macrophages.
Felipe Diaz-Griﬀero shifts our attention to a host depen-
dency factor that is required for HIV-1 infection by expertly
discussing recent advances in elucidating the role of the
karyopherin, TNPO3, in lentiviral replication. Specifically,
this timely review covers recent genetic and biochemical data
showing that the HIV-1’s CA protein is the viral determinant
for the requirement of TNPO3 during infection. Although
the precise role of TNPO3 in lentiviral infection is a hotly
debated topic in the field, this review succinctly frames the
current state of this discussion, thereby providing a much-
needed overview of this fast-moving topic.
The Debyser group has presented a comprehensive
overview on HIV-1 dependency factors (HDFs) involved in
viral integration and nuclear import. The work primarily
discusses LEDGF, an HDF which is critical for mediating
lentiviral integration; we are taken from the early days when
biochemical approaches implicated LEDGF via its physical
association with HIV-1, into the current era, where high-
throughput small-molecule screens have identified novel
inhibitors of this now-well-established host-viral interaction.
The growing field of HIV-1 nuclear import is also covered,
demonstrating the exciting work done in this area after a
transformative whole genome siRNA screen first catalyzed
interest in this fascinating topic. A recapping of the subse-
quent contributions by many laboratories to determine the
mechanism of numerous HDFs in the nuclear import of the
virus is also provided.
Schiralli Lester and Henderson in their review master-
fully integrate the vast amount of data investigating HIV-
1 proviral transcription. With deft skill, the pair interprets
the role played by viral transcription in the rapidly expand-
ing field of HIV-1 latency wherein viral reservoirs resist
eradication after long-term antiviral therapy. Important
topics in proviral transcriptional regulation covered in this
selection include host transcriptions factors, chromatin,
transcriptional interference, and elongation, the latter with
special emphasis on the actions of the viral accessory protein,
Tat. Tat is defined as a critical regulator and therapeutic
target for the alleviation of latency and a potential cure.
Multiple groups in both academia and industry are now
reporting their fascinating investigations of HIV-1 latency,
thus providing a dynamic stage for this prescient eﬀort.
HIV-1 RNA interacts with numerous proteins including
the viral nucleocapsid (NC) protein, and the structure of the
RNA genome is linked to HIV-1 replication. However, the
higher-order structure of the viral RNA is poorly understood.
Sztuba-Solinska and Le Grice have come up with an excellent
review on the utilities of the selective 2′-hydroxyl acylation
analyzed by primer extension (SHAPE) technology, which
can resolve the structure and quantify the flexibility of
RNA at single-nucleotide resolution. The authors provide
an overview of the SHAPE methodology- and also discuss
the benefits and limitations of this technology in studying
the structure of short RNAs. Shape technology has enabled
the resolution of the structure of the entire HIV-1 genome
(∼9750 nucleotides) at the single-nucleotide level, and
such detailed structural understanding could elevate the
viral RNA as a viable target for small-molecule therapeutic
intervention.
Expression of the HIV-1 Gag precursor protein, Pr55Gag,
is suﬃcient to produce virus-like particles. Nascent Gag
traﬃcs to the assembly sites—predominantly the plasma
membrane, where Gag multimerization promotes virus bud-
ding, and finally the host-mediated scission leads to release
of immature particles. Ono and colleagues present a compre-
hensive review on the dynamic association of Gag withmem-
brane microdomains- and survey the role of lipid rafts and
tetraspanin-enriched membrane microdomains in HIV-1
assembly. Besides discussing the more recent understand-
ing of Gag multimer-driven reorganization of membrane
microdomains, the authors also highlight the role of plasma
membrane microdomains in cell-cell spread through viro-
logical synapses in T cells.
Hattleman et al. in their review on retroviral restriction
factors, “TRIM22: a diverse and dynamic antiviral pro-
tein,” investigate another fascinating TRIM family member,
TRIM22. The authors first relate TRIM22’s evolutionary his-
tory including gene expansion/loss and the evidence reveal-
ing that the gene has experienced strong positive selection.
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Interestingly, the authors describe the growing list of viruses
restricted by TRIM22, including encephalomyocarditis virus,
hepatitis B virus, and HIV-1. Lastly, the authors focus on the
latest developments in the cell biology of TRIM22, including
its role in cell proliferation and diﬀerentiation, and in cancer
and autoimmune disease.
HIV-1 Gag, via the C-terminal PTAP motif known as the
“late domain” hijacks the cellular protein Tsg101, a compo-
nent of endosomal sorting complexes required for transport
(ESCRT-1) complex during virus budding. Erlich and Carter
review the role of ESCRT and non-ESCRT proteins in
virus budding and release. The authors describe the role of
PI(4,5)P2 in Gag targeting to the plasma membrane and
the late domain-mediated recruitment of ESCRT machinery
in HIV-1 budding. Recently, the Carter Group reported the
activation of the inositol 1,4,5-triphosphate receptor (IP3R),
which gates intracellular calcium ion stores, as a determinant
in Gag traﬃcking and virus release.
Hammonds, Wang and Spearman provide an excellent
state-of-the-art overview of the rapidly advancing field
of tetherin biology, with a focus on recent advances in
the understanding of the structure and function of this
transmembrane protein. The authors begin by describing the
historical details of the relationship between tetherin and the
HIV-1 accessory factor, Vpu, and then discuss the relevance
of tetherin in the replication and spread of other retroviruses.
Further, the authors present a balanced synopsis of evidence
for and against the model that proposes tetherin localization
to membrane microdomains as a critical determinant of its
antiretroviral activity.
The Env glycoprotein associates with Gag during virus
assembly to form infectious virus particles. Murakami in his
review describes the biosyntheseis, traﬃcking, and incorpo-
ration of Env glycoproteins into virus particles. In this review,
he surveys various proposed models for Env incorporation
into virus particles. The Env incorporation can be passive or
via direct or indirect Gag-Env interaction, which reportedly
occurs at specific membrane microdomains and is mediated
by specific host factors. Murakami’s review covers in detail
the host cellular factors implicated in Gag-Env interactions
and their specific role in virion incorporation.
The HIV-1 PR activity converts immature particles to
infectious mature particles. In her review, Adamson details
the sequential cascade of events that accompany the PR-
mediated cleavage of the Gag polyprotein. Inhibiting PR
activity by protease inhibitors (PIs) results in the production
of noninfectious virus particles, and nine PIs are currently
approved for clinical use. In contrast, maturation inhibitors
bind to Gag and specifically block the individual cleavage
events or alter the order of cleavage events, thereby resulting
in the production of aberrant particles. In this review, Adam-
son provides an overview of the mechanism of action of
PIs and maturation inhibitors- and highlights the problems
associated with drug-resistant mutants.
In their contribution, Hartman and Buckheit review
the HIV inhibitors currently in clinical use, novel HIV RT
inhibitors in the pipeline, and drugs that target additional
viral proteins including the gp41 involved in viral fusion, the
zinc fingers of NC required for viral genome encapsidation
and reverse transcription, the IN inhibitors that block inser-
tion of the viral cDNA into the host cell chromosome, and
the PIs that target viral maturation. The authors also review
molecules that target the HIV-1 regulatory and accessory
proteins Tat, Rev, Vpu, Vpr, and Vif. The review also
examines strategies for targeting host cells proteins (Tsg101
and LEDGF/p75) that are hijacked by HIV for replication,
and ways to exploit intracellular host cell restriction factors
(i.e., APOBEC3 and tetherin) that block HIV replication.
Immunotherapy, gene therapy, and strategies to eliminate the
latent reservoirs of HIV are also described.
Microbicides are chemical entities formulated in a gel,
cream, ring, film, or tablet that can prevent or reduce
transmission of sexually transmitted infections including
HIV infection, when applied to the vagina or rectum. In
their review, Buckheit and Buckheit provide a comprehensive
assessment of the HIV microbicide field and the preclinical
tests that are required for progression of a candidate
microbicide through the development pathway. The authors
also highlight gaps that exist in product development that
relate to product dosing, formulation and delivery, and
pharmacokinetics and pharmacodynamics, which all must
be addressed to improve prioritization of candidate micro-
bicides for clinical testing. Besides vaginal microbicides, the
development and formulation of dual compartment use
microbicides for both vaginal and rectal use are discussed.
The emerging area of multipurpose prevention technologies
with the premise to prevent unplanned pregnancies, HIV,
and other sexually transmitted infections that can increase
HIV acquisition are also described.
A consequence of suboptimal antiretroviral therapy is the
emergence of drug-resistant strains of HIV-1, which can lead
to therapy failure. Much of our knowledge regarding the type
of mutations that emerge during therapy and their role in
decreasing drug susceptibility is derived from studies with
HIV-1 subtype B. However, 90% of HIV-infected individuals
worldwide harbour nonsubtype B variants that contain
distinct polymorphisms. Wainberg and Brenner review the
ability of such polymorphisms in nonsubtype B HIV to aﬀect
the level of resistance mediated by major drug-resistance
mutations, and to modulate the evolution of certain drug
resistance mutations in the presence of drug. The authors
also propose studies that would increase our understanding
of the role of polymorphisms in drug resistance and, thereby,
promote more informed use of first, second and third-line
antiretroviral drugs in diﬀerent geographical settings.
There are few research areas that are not covered explic-
itly in this special issue, such as retrovirus entry, and the role
of receptors and coreceptors in virus entry. However, this
issue oﬀers a comprehensive view of our understanding of
the HIV-1 life cycle, host factors involved in virus replication,
and viral and cellular antiviral drug targets.
Abdul A. Waheed
Abraham L. Brass
Suryaram Gummuluru
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